-
Promising Phase III Data: Sefaxersen Shows Potential in Treating IgA Nephropathy
A New Frontier in Kidney Health Genentech, a member of the Roche Group, recently presented encouraging interim data from a Phase III clinical trial evaluating sefaxersen. The study focuses on patients living with IgA nephropathy (IgAN), a rare and serious autoimmune kidney disease that can significantly impair kidney function over time. Understanding the Study Results…
-
A Breakthrough in Oncology: Divarasib Shows Promise for KRAS G12C-Mutated Cancer
Advancing Precision Oncology Genentech, a member of the Roche Group, recently unveiled promising clinical trial results for divarasib, a novel therapeutic agent designed to target specific genetic mutations in cancer. As the landscape of oncology shifts toward personalized medicine, this drug is emerging as a potential ‘best-in-class’ treatment for patients with KRAS G12C-mutated solid tumors…
-
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
South San Francisco, CA — October 15, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of… Source: Read More
-
FDA Approves Tecentriq Combination as Adjuvant Therapy for Specific Colon Cancer
A New Milestone in Colon Cancer Treatment Genentech has announced a significant development in oncology with the FDA approval of Tecentriq (atezolizumab) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy. This treatment is now indicated as an adjuvant therapy for patients with stage IIB or IIC colon cancer that has been completely resected. Understanding the Indication…
-
Promising Breakthrough: Genentech’s Sefaxersen Shows Significant Promise for IgA Nephropathy
A New Hope for IgA Nephropathy Patients Recent clinical developments have brought a glimmer of hope to those suffering from IgA nephropathy (IgAN), a chronic autoimmune kidney disease. Genentech, a member of the Roche Group, recently announced positive interim data from their clinical trial of sefaxersen, an investigational therapy designed to tackle the underlying causes…
-
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
South San Francisco, CA — September 30, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with… Source: Read More
-
A Breakthrough Alliance: IDEAYA and Genentech Join Forces to Target Pancreatic Cancer
NASDAQ: $IDYA A Strategic Leap in Precision Oncology In a significant development for oncology research, IDEAYA Biosciences has officially announced a new clinical trial collaboration with Genentech, a member of the Roche Group. This partnership aims to tackle one of the most challenging areas in cancer treatment: MTAP-deleted, KRAS G12D mutant pancreatic cancer. The Power…